Shanghai Xiao Fang Pharmaceutical Co., Ltd. Class ASSE: 603207

"SHANGHAI XIAO FANG PHARMACEUTICAL CO., LTD."Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report

Jul 15, 2026 · Issued by Shanghai Xiao Fang Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange

Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis

Earlier from Shanghai Xiao Fang Pharmaceutical Co., Ltd. Class A

"SHANGHAI XIAO FANG PHARMACEUTICAL CO.,LTD."Announcement on the Resignation of the Independent DirectorsJul 2
Announcement on the 1st Granting of Restricted Stocks to Incentive Objects in 2026 Restricted Stock Incentive PlanJun 30
Announcement on Implementation of Dividend Distribution for 2025Jun 26
Publicity Explanation and Verification Opinions of the Remuneration and Appraisal Committee of the Board of Directors on List of Initially Granted Incentive Objects in the 2026 Restricted Stock Incentive PlanJun 25

All Shanghai Xiao Fang Pharmaceutical Co., Ltd. Class A news releases